BioSpace News Archive

Avidity Biosciences, Inc. today announced that Avidity management will be participating at the following upcoming conferences.

Onco360 has been selected as a pharmacy partner by GlaxoSmithKline for OJJAARA™ (momelotinib). OJJAARA is a kinase inhibitor indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.

A peer-reviewed study in the Journal of the American College of Cardiology: Clinical Electrophysiology (JACC-EP) has found a significant reduction in the rate of atrioesophageal fistulas (AEFs) during cardiac ablation of the left atrium when using Attune Medical’s ensoETM proactive esophageal cooling device compared to luminal esophageal temperature monitoring

Today, Vernier Science Education, a leading provider of innovative science and STEM education solutions, announced a significant organizational shift that will chart the course for its mission and values for the foreseeable future.

hC Bioscience has appointed Jose Lora, Ph.D., as its Chief Scientific Officer (CSO). In this position, Lora will play a pivotal role in helping to shape the Company’s strategic direction around its innovative portfolio of therapeutic tRNAs and advancing their lead candidates into the clinic.

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the first subject has been dosed in the Company’s landmark Phase 1b/2a proof-of-concept placebo-controlled clinical trial for its proprietary lead compound, NVG-291, in individuals with spinal cord injury (SCI).

Neuroendocrine Cancer treatment response test, PPQ, delivers 96% accuracy

ACG, a leading supplier of fully integrated manufacturing solutions to the global pharmaceutical and nutraceutical industries, is pleased to announce the appointment of Borja Guerra as the vice president for international sales.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., strengthening the company’s gene therapy and auditory programs.

Inovalon today announced that its annual Customer Congress will take place from October 15-17, 2023 in Washington, D.C.